Skip to main content

Table 4 Coincidence of autoantibody subtypes with anti-MCV IgA (AMCV IgA)-positive and -negative patients respecting seropositivity and mean titers at baseline

From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

  

AMCV IgA-positive patients

AMCV IgA-negative patients

Mann–Whitney U P value

(n = 21)

(n = 29)

AMCV IgG

positive (%, n)

100 % (21/21)

100 % (29/29)

 
 

negative (%, n)

0

0

 
 

mean titer (U/ml)

1128.58

548.13

0.012

 

SD (U/ml)

1160.25

573.98

 

AMCV IgM

positive (%, n)

71 % (15/21)

34 % (10/29)

 
 

negative (%, n)

29 % (6/21)

66 % (19/29)

 
 

mean titer (U/ml)

98.65

27.1

0.005

 

SD (U/ml)

157.69

47.63

 

RF IgG

positive (%, n)

10 % (2/21)

3 % (1/29)

 
 

negative (%, n)

90 % (19/21)

97 % (28/29)

 
 

mean titer (IU/ml)

16.42

9.54

0.013

 

SD (IU/ml)

15.62

14.13

 

RF IgM

positive (%, n)

71 % (15/21)

48 % (14/29)

 
 

negative (%, n)

29 % (6/21)

52 % (15/29)

 
 

mean titer (IU/ml)

83.47

34.96

0.071

 

SD (IU/ml)

103.29

51.77

 

RF IgA

positive (%, n)

81 % (17/21)

41 % (12/29)

 
 

negative (%, n)

19 % (4/21)

59 % (17/29)

 
 

mean titer (IU/ml)

161.68

88.66

0.003

 

SD (IU/ml)

137.91

120.54

 

ACCP IgG

positive (%, n)

100 % (21/21)

86 % (25/29)

 
 

negative (%, n)

0 % (0/21)

14 % (4/29)

 
 

mean titer (U/ml)

1262.77

989.99

0.253

 

SD (U/ml)

597.03

776.62

 
  1. ACCP, antibodies against cyclic citrullinated peptide; AMCV, antibodies against mutated citrullinated vimentin; n, number of patients; NRRs, non-responders to RTX; RF, rheumatoid factor; RRs, responders to RTX; RTX, rituximab; SD, standard deviation